Cihui Yan

State Key Laboratory Of Druggability Evaluation And Systematic Translational Medicine, Key Laboratory Of Cancer Immunology And Biotherapy
Tianjin, 300060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Circulating CD28-KLRG1+CD8+ T cells involve in systemic and local immunity that predicts chemoimmunotherapy outcomes in advanced NSCLC.

Circulating CD28-KLRG1+CD8+ T cells involve in systemic and local immunity that predicts chemoimmunotherapy outcomes in advanced NSCLC.

Journal: Journal of translational medicine

Published: May 21, 2026

Mesenchymal stem cell-induced metabolic reprogramming of EGFR-wild-type tumor cells drives therapeutic resistance in EGFR-mutant non-small cell lung cancer.

Mesenchymal stem cell-induced metabolic reprogramming of EGFR-wild-type tumor cells drives therapeutic resistance in EGFR-mutant non-small cell lung cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: January 24, 2026

Development and external validation of two nomograms for predicting brain metastases and brain metastasis-free survival in primary small cell carcinoma of the esophagus: a retrospective multicenter analysis.

Development and external validation of two nomograms for predicting brain metastases and brain metastasis-free survival in primary small cell carcinoma of the esophagus: a retrospective multicenter analysis.

Journal: Therapeutic advances in medical oncology

Published: January 13, 2026

Iparomlimab and tuvonralimab (QL1706) combined definitive chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma (QL1706-IIT-02): a single arm, phase 2 trial.

Iparomlimab and tuvonralimab (QL1706) combined definitive chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma (QL1706-IIT-02): a single arm, phase 2 trial.

Journal: EClinicalMedicine

Published: September 04, 2025

Efficacy and safety of radiotherapy in first-line treatment for de novo advanced esophageal cancer in the era of immunochemotherapy: a systematic review and meta-analysis.

Efficacy and safety of radiotherapy in first-line treatment for de novo advanced esophageal cancer in the era of immunochemotherapy: a systematic review and meta-analysis.

Journal: BMC cancer

Published: July 02, 2025

IL-15 signaling via cis- and trans-presentation to progenitor-exhausted CD8+ T cells enhances radio-immunotherapy efficacy in ESCC.

IL-15 signaling via cis- and trans-presentation to progenitor-exhausted CD8+ T cells enhances radio-immunotherapy efficacy in ESCC.

Journal: Journal of nanobiotechnology

Published: March 05, 2025

Causal relationships between immunophenotypes, plasma metabolites, and pancreatic cancer: a mediation Mendelian randomization study.

Causal relationships between immunophenotypes, plasma metabolites, and pancreatic cancer: a mediation Mendelian randomization study.

Journal: Journal of leukocyte biology

Published: February 25, 2025

Determining the optimal radiation dose for locally advanced esophageal cancer: A pooled analysis of reconstructed individual patient data from randomized clinical trials.

Determining the optimal radiation dose for locally advanced esophageal cancer: A pooled analysis of reconstructed individual patient data from randomized clinical trials.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: November 20, 2024

Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era.

Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era.

Journal: Expert opinion on biological therapy

Published: October 26, 2024

Survival benefit and spatial properties of tertiary lymphoid structures in esophageal squamous cell carcinoma with neoadjuvant therapies.

Survival benefit and spatial properties of tertiary lymphoid structures in esophageal squamous cell carcinoma with neoadjuvant therapies.

Journal: Cancer letters

Published: March 26, 2024

Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: a multicenter, randomized, parallel-controlled, phase II clinical trial.

Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: a multicenter, randomized, parallel-controlled, phase II clinical trial.

Journal: BMC cancer

Published: February 20, 2024

Correction: In vitro CRISPR screening uncovers CRTC3 as a regulator of IFN-γ-induced ferroptosis of hepatocellular carcinoma.

Correction: In vitro CRISPR screening uncovers CRTC3 as a regulator of IFN-γ-induced ferroptosis of hepatocellular carcinoma.

Journal: Cell death discovery

Published: December 18, 2023

Showing 1-12 of 37

Last Updated: 09/26/2026